Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension

Hypertension. 2021 Sep;78(3):604-616. doi: 10.1161/HYPERTENSIONAHA.121.17041. Epub 2021 Jul 26.

Affiliations

¹ Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.A.-L., A.C.M., K.B.N., A.H., F.J.R., D.S.S., T.J.G., D.G., R.M.T.).
² Institute of Infectious Disease and Molecular Medicine and Division of Medical Biochemistry, University of Cape Town, South Africa (L.B.A., E.S.).
³ Attoquant Diagnostics GmbH, Vienna, Austria (M.P).

Abstract

[Figure: see text].

Keywords: blood pressure; neprilysin; omapatrilat; permeability; vasodilatation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aminobutyrates / pharmacology*
Aminobutyrates / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Animals
Antihypertensive Agents / pharmacology*
Antihypertensive Agents / therapeutic use
Biphenyl Compounds / pharmacology*
Biphenyl Compounds / therapeutic use
Blood Pressure / drug effects*
Body Weight / drug effects
Hypertension / drug therapy*
Hypertension / metabolism
Lisinopril / pharmacology*
Lisinopril / therapeutic use
Liver / drug effects
Liver / metabolism
Mice
Mice, Transgenic
Neprilysin / antagonists & inhibitors*
Pyridines / pharmacology
Pyridines / therapeutic use
Renin / metabolism
Thiazepines / pharmacology
Thiazepines / therapeutic use

Substances

Aminobutyrates
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Biphenyl Compounds
Pyridines
Thiazepines
sacubitril
omapatrilat
Lisinopril
Renin
Neprilysin

Grants and funding